Literature DB >> 26176402

Delamanid for Extensively Drug-Resistant Tuberculosis.

Rajesh Gupta1, Lawrence J Geiter, Charles D Wells, Mengqui Gao, Andra Cirule, Heping Xiao.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26176402     DOI： 10.1056/NEJMc1415332

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  22 in total

Review 1.  Antibiotics in the clinical pipeline at the end of 2015.

Authors:  Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

2.  An update on multidrug-resistant tuberculosis .

Authors:  Mirae Park; Giovanni Satta; Onn Min Kon
Journal:  Clin Med (Lond)       Date:  2019-03       Impact factor: 2.659

Review 3.  Drug-resistance in Mycobacterium tuberculosis: where we stand.

Authors:  Amanda Mabhula; Vinayak Singh
Journal:  Medchemcomm       Date:  2019-06-11       Impact factor: 3.597

4.  A Protein Complex from Human Milk Enhances the Activity of Antibiotics and Drugs against Mycobacterium tuberculosis.

Authors:  Virginia Meikle; Ann-Kristin Mossberg; Avishek Mitra; Anders P Hakansson; Michael Niederweis
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

5.  MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration.

Authors:  Kelly Stinson; Natalia Kurepina; Amour Venter; Mamoru Fujiwara; Masanori Kawasaki; Juliano Timm; Elena Shashkina; Barry N Kreiswirth; Yongge Liu; Makoto Matsumoto; Lawrence Geiter
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

Review 6.  Physiology, Biochemistry, and Applications of F420- and Fo-Dependent Redox Reactions.

Authors:  Chris Greening; F Hafna Ahmed; A Elaaf Mohamed; Brendon M Lee; Gunjan Pandey; Andrew C Warden; Colin Scott; John G Oakeshott; Matthew C Taylor; Colin J Jackson
Journal:  Microbiol Mol Biol Rev       Date:  2016-04-27       Impact factor: 11.056

Review 7.  Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill.

Authors:  Aliasgar Esmail; Natasha F Sabur; Ikechi Okpechi; Keertan Dheda
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 8.  Cholesterol metabolism: a potential therapeutic target in Mycobacteria.

Authors:  Areej Abuhammad
Journal:  Br J Pharmacol       Date:  2017-01-24       Impact factor: 8.739

Review 9.  Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings.

Authors:  Derek J Sloan; Joseph M Lewis
Journal:  Trans R Soc Trop Med Hyg       Date:  2016-03       Impact factor: 2.184

Review 10.  Delamanid expanded access novel treatment of drug resistant tuberculosis.

Authors:  Roxana Rustomjee; Alimuddin Zumla
Journal:  Infect Drug Resist       Date:  2015-10-29       Impact factor: 4.003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.